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Effects of neurohypophyseal antagonists in postnephrectomy natriure-
sis in male rats. Acute unilateral nephrectomy (AUN) in anesthetized
male Lewis x DA rats induced rapid and consistent increases in
electrolyte and fluid excretion by the remaining kidney during the first
hours. Continuous infusion of a vasopressin (AVP) V1-receptor antag-
onist d(CH2)5Tyr(Me)AVP (V1-ant) reduced renal electrolyte and fluid
excretion before and after AUN to a similar extent, whereas an
oxytocin (OT)-receptor antagonist [Mpa' ,D-Tyr(Et)2,Thr4,Orn8}-OT(CAP) at the same dose selectively attenuated the increase in sodium
excretion after AUN. The plasma concentration of OT rose significantly
after AUN (9.16 1.4 to 21.45 5.07 pg ml'). A similar OT level
obtained by infusion of OT mimicked the renal responses to AUN
without elevating blood pressure; however, only CAP but not V,-ant
efficiently reversed OT-induced natriuresis. Also, the infusion of CAP
at the same dose produced no effects on the rise of blood pressure
caused by AVP while the infusion of the V,-ant prevented such a rise.
Thus, CAP reduced the natnuresis after AUN by interfering with OT-
and not V,-receptors. In conclusion, evidence is presented, for the first
time, concerning the major role of OT receptors in the acute readjust-
ment of the renal sodium excretion after AUN, and a synergistic role for
AVP in terms of the general magnitude of renal excretion.
The surgical removal of one kidney in experimental animals
and patients started more than one century ago, but the
mechanism of the immediate adjustment of the salt and water
balance in the new situation still remains unclear. Sodium
homeostasis is so important for the internal environment that
the regulatory system may well involve more than one mecha-
nism.
Recently, it has been proposed that the postnephrectomy
natriuresis is a consequence of alterations in neurohormonal
systems which regulate sodium balance. These systems are
dependent on renal nerves [1, 21, an intact pituitary [3], and
other humoral factors [4, 5]. Since the release of neurohypophy-
seal peptide is known be associated with alterations of extra-
cellular fluid volume and osmolality, mainly sodium [6], we
decided to test whether these hormones were necessary for the
acute adjustments taking place in the remaining kidney follow-
ing nephrectomy.
Accumulating evidence indicates that both oxytocin and
vasopressin may possess natriuretic properties, and that both
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are released in response to osmotic stimuli [6—15]. We have also
shown that AVP V,-receptor antagonists are potent inhibitors
of the natriuresis occumng after elevating the Na concentration
in the lateral cerebral ventricles [16]. To evaluate the involve-
ment of the neurohypophyseal peptide in the postnephrectomy
natriuresis, we used d(CH2)5Tyr(Me)AVP, an antagonist
to the vasopressin vascular V,-receptor and [Mpa',D-Tyr
(Et)2,Thr4,Orn8]-OT, an antagonist to the OT receptor.
Methods
Animals
Adult male Fl hybrids of Lewis x DA rats from our own
breed weighing 250 to 380 g were used. Lewis and DA rats were
purchased from ZFV, Hannover, Germany. Prior to the exper-
iments, all animals had free access to tap water and a standard-
ized chow (R3, Ewos, Sodertalje, Sweden) containing 3 g
Na/kg, 8 g K/kg and 13 Megajoule/kg.
Drugs
We used synthetic vasopressin and oxytocin (Ferring,
MalmO, Sweden), a V,-antagonist [1-(f3-mercapto-J3,3-cyclo-
pentamethylenepropionic acid), 2-(O-methyl)Tyr]Arg-vaso-
pressin (d(CH2)5Tyr(Me)AVP (Sigma Chemical Co., St. Louis,
Missouri, USA) and an OT antagonist [l-(3-mercaptopropionic
acid), 2-O-ethyl-D-Tyr, 4-Thr, 8-Orn]-oxytocin (CAP, Ferring,
Malmö, Sweden). Their molecular structure and properties are
shown in Figure 1.
General surgical procedures
The animals were anesthetized intraperitoneally with Inact-
1R (Byk-Gulden, Konstanz, Germany), 120 mg/kg body weight
and placed on a servo-controlled heating pad to maintain the
rectal temperature close to 37.5°C.
After tracheostomy the left feinoral vein was cannulated for
continuous infusion (5 ml . hr' . kg' body wt) of a Ringer
solution containing (in mM) 129 NaCI, 2.5 KC1, 25 NaHCO3 and
0.75 CaCI2, to compensate for fluid losses during the experi-
ment, and this also served as a vehicle for drug administration.
The left femoral artery was cannulated for continuous recording
of blood pressure. The bladder was catheterized through a
suprapubic incision.
Renal maneuver
The left kidney was exposed by a sub-costal flank incision
and a ligature was placed loosely around the pedicle of the
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Fig. 1. The structures of the V1-antagonist
(V1-antag), arginine vasopressin (A VP),
oxytocin antagonist (OT-antag or CAP) and
oxytocin (OT) used in this study.
kidney. The incision was then closed with clips. A 45-minutes
recovery period was allowed, followed by four urine collection
periods of 15 minutes each. Urine was collected into pre-
weighed plastic vials. After the completion of these control
collections, the sub-costal incision was opened again. In the
AUN experiments, the renal pedicle was tied by the previously
placed ligature and the kidney was not removed; in sham
experiments, the renal area was exposed and the ligature was
removed. Immediately after the incision was closed, another
four urinary samples were collected every 15 minutes.
Three groups of rats were studied.
Vehicle group. Ringer solution alone (5 ml hr' kg' body
wt) was infused intravenously throughout the experiment of
two hours. The rats underwent one of the following two surgical
procedures: (a) vehicle AUN, N = 16; (b) vehicle sham
operation, N = 10.
V1-ant group. These rats received the V,-antagonist. Just
before the control periods, the V1-antagonist was given as a
bolus injection (40 tg kg' body wt) in a volume of 100 tl.
This was followed by a continuous infusion of V1-antagonist (40g• hr . kg' body wt), which was added to the ongoing
intravenous infusion of Ringer. The two subgroups were: (a)
V,-ant AUN, N = 5; (b) V,-ant sham operation, N 5.
CAP group. The procedures and dose were the same as
above, with the exception that CAP was used as the antagonist.
The two subgroups were: (a) CAP AUN, N = 9; (b) CAP sham
operation, N = 7.
Additional protocol
The surgical preparations were made as previously de-
scribed.
AVP infusion experiments. The effects of neurohypophyseal
antagonists on the response to the exogenous AVP were tested.
These rats were all given a 30-minute infusion of AVP (0.5
jg hr' . kg body wt) in the middle of the experiments,
preceded by a 15-minute collecting period and followed by
30-minute collecting period which served as control periods.
The control group received only Ringer solution at the rate of
5 ml hC' kg' body wt throughout the 30-minute recovery
period and the 75-minute recording period. This group is
referred to as the "noHex control" group, where "noHex"
indicates that these animals did not receive hexamethonium
(see below).
In the other two groups, the intravenous infusion contained
either d(CH2)5Tyr(Me)AVP or CAP, both of which were in-
fused at the same dose as used in the AUN experiments (the
"noHex V,-ant" and "noHex CAP" groups). Urine samples
were collected at 15-minute intervals.
Considering that the baroreceptor reflex partly counteracts
the hypertensive effect of AVP, we repeated the preceding
experiments, adding the ganglionic blocker hexamethonium (30
mg hr' . kg—'; Serva, Heidelberg, Germany) to the continu-
ous Ringer infusion, to unmask the vascular effect of AVP.
These are referred to as the "Hex control," the "Hex V1-ant"
and the "Hex CAP" groups.
OT infusion experiments. The effects of neurohypophyseal
antagonists on the response to the exogenous OT were tested.
These rats were all given a 60 minute infusion of OT (25
ng hr' kg' body wt) after a 60-minute control period
except in the "control" group which was infused with Ringer
solution instead of OT.
In the "OT V1" and "OT CAP" groups, the intravenous
infusion contained either V,-ant or CAP initiated at the begin-
ning of the control period and continued throughout the whole
experiment, both of which were infused with the same dose as
used in the AUN experiments, whereas the "OT" group
received only pre-infusion of Ringers solution. Urine samples
were collected at 20 minute intervals.
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Analysis of urine. The urine volume was measured gravimet-
rically and calculated in terms of the excretion by an individual
kidney in AUN and sham operation series experiments. Uri-
nary sodium and potassium concentrations were determined by
flame photometry (FLM3, Radiometer, Denmark). The osmo-
lality was measured by the freezing point depression (Model
3M0, Advanced Instruments Inc., Massachusetts, USA).
Radioimmunoassay (RIA) of OT and AVP. OT and AVP
were assayed in the same blood samples. At the end of
experiments, 3 to 4 ml artery blood samples were collected in an
ice-bath tube containing 5% Na2EDTA (rats were still con-
nected to the infusion pump), then immediately were centri-
fuged at 1100 g and 4°C for 15 minutes, and the plasma samples
were then stored in —70°C. The samples were extracted using
solid phase Bakerbond spe-C18 columns (J.T. Baker, Phil-
lipsburg, USA). The eluted fractions were dried in a Speed Vac
concentrator (Savant), and the residues were reconstituted in
0.1 M phosphate buffer containing 0.02% NaN3, 0.1% human
serum albumin, pH 7.6. The incubation mixture consisted of
200 j.d neurohypophyseal peptide standard (range 2.5 to 1280
pg/mi) or samples, 100 d antiserum and 100 d iodinated
peptide (4000 CPM). A disequilibrium system was used: stan-
dard/sample and antibody were pre-incubated for three hours at
4°C. Then tracer was added for another 48 hours at 4°C. After
incubation, separation of bound and free radioactivity was
performed by adding 500 sl plasma coated charcoal followed by
centrifugation at 1800 g for 20 minutes at 4°C. Radioactivity in
the supernatant was counted with a CompuGamma CS gamma
counter (LKB WALLAC, Turku, Finland). The assays were
performed in duplicate.
RIA of OT. Antiserum RI3 (Division of Neurophysiology and
Neuropharmacology, MRC, London, UK), dilution 1:40,000
was used. The cross reactivity of RI3 with vasopressin was
0.012%. The assay sensitivity was 5 pg/mI, intraassay coeffi-
cient of variation (cv) was 11% and interassay cv was 16%.
Recovery of oxytocin from exogenous enriched plasma was
84.6%.
RIA of AVP. Antiserum AS (Ferring, MalmO, Sweden),
dilution 1:400,000 was used. The cross reactivity of A8 with
oxytocin was <0.1%. The assay sensitivity was 0.31 pg/mi,
intraassay cv was 8.4% and interassay cv was 20.5%. Recovery
of vasopressin from exogenous enriched plasma was 94.2%.
Statistics
All data are presented as means SEM. The effects of AUN
and the effects of AVP on renal function were analyzed by
analysis of variance (ANOVA) with a repeated measures de-
sign, followed by the Tukey post-hoc test applied within each
group. Comparisons between groups were made with the two-
way ANOVA followed by Bonferroni adjusted f-test, and were
also made with a f-test for the average value of periods (0 to 60
mm) before AUN and the average excretion 30 to 60 minutes
after AUN. A P value of less than 0.05 was considered to be
statistically significant.
Results
The urine flow rate ('O, excretion of sodium (UNaV), potas-
sium (UKY) and urine osmolality (Osm) in the vehicle group are
presented in Figure 2. The renal functions of two subgroups,
"vehicle AUN" and "vehicle sham", were constant during a
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Fig. 2. The mean (± SCM) values of sodium excretion (UNi'), potas-
sium excretion (UKV), urine flow rate (V) and urine osmolalisy (U0,,.), in
the vehicle control group [divided into (•) AUN and (0) sham sub-
groupsJ; the arrow indicates the time of the A UN or sham operation. ** P
<0.01 compared with the corresponding value in the control periods (0 to
60 mm) based on paired analysis of variance followed by the Bonferroni
adjustment.
control period of one hour. Alter nephrectomy, the remaining
kidney in the "vehicle AUN" group showed a gradual increase
in V, UNaV and UKV. Moreover, in most cases a transient
increase in MAP (from 120.3 1.6 to 130 2 mm Hg) was
observed for about three to eight mm after AUN, which is only
comparable in the "CAP AUN" group (from 118.4 3.8 to
128.7 4 mm Hg; Fig. 3).
In the "vehicle sham" group the sham operation produced no
significant changes in any of the measured variables.
The effects of both antagonists on the renal response to AUN
are shown in Figure 4. In the V1-ant AUN group, the baseline
UNaV, UKV and V were significantly reduced compared with
the other groups, suggesting that this dose of V1-ant influenced
renal electrolyte and fluid excretion even prior to AUN. It also
reduced the fractional increases after AUN, but did not block
them. In the CAP AUN group only the increment of UNaV after
AUN was attenuated almost without any changes in other
measured variables.
In the AVP infusion experiments, the groups that were
treated with hexamethonium had a basic blood pressure that
0
E
z
0
E
0
U-
1.0 I I
0.8
1.5
1
**
6'
1
**
**
Huang et a!: VI- and oxytocin-antagonist and AUN 695
was decreased by approximately 37 mm Hg as compared with
the groups that received only the Ringers solution (Fig. 5).
The infusion of AVP caused a rise of MAP from 136.3 4.5
to 143.8 6.4 mm Hg in the no hexamethonium control group,
and from 99.5 3.0 to 122.3 1.1 mm Hg in the hexametho-
nium control group. The infusion of V1-ant completely abol-
ished such a rise in MAP caused by AVP, both in the noHex
V1-ant group and in the Hex V1-ant group, whereas CAP had no
such effects on the MAP response to AVP infusion (Fig. 5).
The renal excretions in the three groups without hexametho-
nium are shown in Table 1. When AVP was given in a dose
sufficient to cause a rise of blood pressure, this was accompa-
nied by an increase in renal excretion of electrolyte and fluid
with a slight reduction of osmolality. Such renal effects of AVP
infusion shown in control groups were completely abolished by
treatment with the V1-ant, whereas CAP did not change the
renal effects of AVP infusion. The same pattern also holds true
for the groups treated with hexamethonium (data not shown).
The basal plasma OT and AVP levels (in the Ringers infusion
control group) were similar to those in the "vehicle sham"
group, and both increased in the "vehicle AUN" group, but
only the OT level changed significantly (Fig. 6).
An infusion of OT (25 ng hr kg body wt) induced a
plasma OT concentration similar to that in the "vehicle AUN"
group (Fig. 6a) and mimicked renal electrolyte and fluid excre-
tion after AUN without raising the blood pressure (Figs. 7, 8).
On the contrary, 25 ng hr' . kg body wt infusion of AVP
which elevated the AVP concentration to a similar extent as
seen after AUN caused neither changes in MAP nor renal
electrolyte and fluid excretion. This is consistent with another
finding [17].
The same dose of CAP treatment as that used in AUN
Veh V1 CAP
Fig. 4. The mean (±sEM) effects of AUN on sodium excretion (UN'),
potassium excretion (UV), urine flow rate (V) and urine osmolality
(U0,,), in control animals and animals infused with d(CH2)3Tyr(Me)AVP
and CAP, The lower part of each bar () represents the average value of
periods (0 to 60 mm) before AUN, the upper part of each bar (0)
represents the average excretion 30 to 60 minutes after AUN. ** P < 0.01
from Vehicle AUN group based on unpaired 1-test applied between three
groups for the average excretion 30 to 60 minutes after AUN.
experiments completely abolished the OT-induced natriuresis
while V1-ant only slightly attenuated it (Fig. 9).
CAP treatment reversed the renal excretion responses to
exogenous OT in a pattern similar to that observed in the "CAP
AUN" group, except for the UKV increase (Figs. 4, 8).
Discussion
To investigate the early renal functional changes in response
to AUN, we studied the time course of the gradual compensa-
tory increase in electrolyte and fluid excretion in the first hours
following contralateral nephrectomy. This postnephrectomy
natriuresis is in agreement with previous findings from other
laboratories [1, 3, 4, 18—20], whereas sham operation (vehicle
sham, V1 sham and CAP sham subgroups) produced no signif-
icant changes in any of the variables measured.
The continuous infusion of CAP itself does not produce
significant alteration in baseline cation excretion, that is, the
basal rates of electrolyte excretion were similar in the vehicle
group and CAP group during the initial control periods (Fig. 4).
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Fig. 3. The mean (±sEM) values of arterial mean pressure (MAP) in
the (--) "vehicle A UN", (-G-) "vehicle sham operation", (-V-) "CAP
A UN" and (-v—) "V1-ant A UN' groups. The arrow indicates the time of
the AUN or sham operation.
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Accordingly, the attenuation of the adaptive function respon-
sive to AUN can be attributed to the blockade of the OT
receptor by its antagonist.
The continuous infusion of the vasopressin vascular V1
receptor antagonist reduced both the basal and postnephrec-
tomy renal excretion of fluid and electrolyte to a similar extent
(Fig. 4). This could be interpreted, in the light of an approxi-
mately 7 mm Hg blood pressure fall after the infusion of V1-ant
(Fig. 3), as triggering a vasoconstrictor reflex, since the AVP
vascular V1-receptor together with sympathetic nerves and
renin-angiotensin maintains vasculature tone [21]. This is also
true of the AVP infusion experiments (Fig. 5; Table 1).
AVP and OT are closely related as are their antagonists. In
our experiments, urine osmolality did not change significantly
after the loss of the contralateral kidney (Figs. 2, 4), and free
water clearance did not differ significantly between the "vehicle
AUN" and "vehicle sham" groups (—24.08 5.66 vs. —21.59
1.07 p1/mm). This indicates that there is not greater change in
V2-receptor activity involved in the postnephrectomy natriure-
sis [22]. Both d(CH2)5Tyr(Me)AVP (weak V2-agonist) and CAP
(weak V2-antagonist) have little effects on the V2-receptor [23,
24]. Additional experiments were therefore performed to deter-
mine whether or not the dose of the antagonists used in the
AUN experiments were sufficient to antagonize their respective
receptors, and also to determine their specificity on vasopressin
vascular V1-receptors and oxytocin receptors.
In AVP infusion experiments, the infusion of d(CH2)5
Tyr(Me)AVP at the same dose as used in the AUN experiments
completely prevented the rise of blood pressure caused by AVP,
while the infi.ision of the same dose of CAP produced no effect
(Fig. 5). This indicates that this dose of the V1-ant is sufficient to
block its receptor. Moreover, the infusion of AVP at a pressor
dose of 0.5 p.g hC' .kg body wt caused a simultaneous
increase in MAP and renal excretion of electrolyte and fluid.
These results support the view that the natriuresis elicited by AVP
alone was closely related to the pressor action of the hormone; in
other words, it was dependent on the vasopressin vascular V1.
receptor [15—17,21]. The lack of effects of CAP on the rise of MAP
and on the increase of renal electrolyte and fluid excretion caused
by AVP shows that the OT-receptor antagonist does not cross
react with the V1-receptor, which mediates both systemic hemo-
dynamic and renal actions of AVP (Fig. 5; Table 1). In this respect
CAP at this dose has a high specificity for OT-receptors.
In OT infusion experiments, an infusion rate of 25 ng
1 . kg' body wt was selected from the dose response
curves in order to reach a similar plasma OT concentration as
seen in "vehicle AUN" group (Fig. 6a). This infusion mimicked
the renal response to unilateral nephrectomy without elevating
blood pressure (Figs. 7, 8). The same dose of both neurohy-
—
pophyseal antagonists was tested again in this situation. CAP
80 completely blocked the 01-induced natriuresis, whereas the
attenuation by the V1-ant did not reach statistical significance
(Fig. 9).
Thus, the experiments involving infusion of neurohypophy-
seal peptide and their antagonists clearly demonstrate that, in
our experimental set-up, CAP mainly antagonized OT acting on
OT receptors and V1-ant mainly antagonized AVP acting on V1
receptors with a minor effect on OT receptors [25].
According to the RIA results, one hour after AUN, the
plasma OT concentration (Fig. 6a) was elevated, though still
within the physiological range [26], in the "vehicle AUN"
group. A similar plasma OT concentration induced by 01
infusion could mimic the natriuresis, kaliuresis and diuresis
seen after AUN (Figs. 2, 8), whereas a plasma AVP concentra-
tion similar to that in "vehicle AUN" did not. Moreover,
sodium excretion still increased more than threefold after AUN
in the "V1-ant AUN" group. These results indicate that OT
plays an essential role in the postnephrectomy natriuresis.
AVP, however, has a more general effect on renal excretion,
possibly by interfering with other modulators of vascular tone
(such as the renin-angiotensin system, sympathetic nerves).
This notion is supported by the demonstration a postnephrec-
tomy natriuresis in the AVP deficient Brattleboro rats [27].
The apparent discrepancy between the CAP blockages in
both AUN and exogenous OT induced kaliuresis (Figs. 4, 8)
indicates that the increase in UKV after AUN may be regulated
by factors other than 01. This is consistent with another finding
which claimed that the natriuresis and the kaliuresis seen after
AUN may be due to different mechanisms [28].
CAP failed to block diuresis seen after both AUN and OT
infusion whereas the infusion of OT induced diuresis (Figs. 4,
8). These findings raised the possibility that OT influenced the
urine flow rate by some mechanism [13, 22], which is not
reversed by the OT uterine-like receptor antagonist CAP, or
there may be a non-uterine-like subtype OT receptor in the
kidney regulating urine flow rate. Accordingly, 01 is probably
responsible not only for the natriuresis, but also for diuresis
after AUN.
It has also been claimed that oxytocin influenced both the
glomerular filtration rate (GFR) and the tubular handling of
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Fig. 5. Mean arterial blood pressure (MAP) before, during and after
the infusion of arginine vasopressin (A VP) in (I) "Hex control" or
"noHex control" groups, (0) "Hex V1-ant" or "noHex V,-ant"
groups and (V) "Hex CAP" or "noHex CAP" groups. In each group
N = 4. Values are means SEM. Abbreviation is Hex, hexamethonium.
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Table 1. The effects of AVP and neurohypophyseal antagonists on renal excretion
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sodium but that the effects of OT on electrolyte and on fluid
excretion were independent of each other [7, 12].
Thus, OT may play a role as an endogenous nonhypertensive
natriuretic agent apart from its reproductive function in females
[13, 14]. There have been numerous reports of OT infusion
during dehydration, normal-hydration, hydration, salt loading
and salt depletion [7, 8, 11, 12, 26]. The natriuretic property of
OT persists during negative or positive water and salt balances.
However, the magnitude of the response varies depending on
experimental conditions, which is not surprising since the basic
plasma concentrations of the neurohypophyseal peptide vary as
osmolality change [29].
By using an autoradiographic technique in the rat kidney,
Stoeckel and Freund-Mercier showed that there are OT binding
sites on macula densa cells. These cells are involved in the
tubuloglomerular feedback mechanism and renin release [30].
This result has recently been confirmed by Schmidt et a! [31].
Considering the high affinity of AVP for the OT-receptor, they
have emphasized the possibility that some renal effects ascribed
to AVP acting through V,-receptors may in fact be mediated by
OT-receptors.
Period
Time mm
AVP
1
0—15
—
2
15—30
+
3
30-45
4
45—60
-
5
60—75
-
V pJ/min
Control 3.65 0.47 4.10 0.37 {7.58 o79}a {7.05 O.85}a 4.45 0.52
V,-ant 2.38 0.09 2.43 0.18 2.70 0.18 2.65 O.14c 3.23 0.68
CAP 3.20 0.32 3.90 0.65 9.18 3.47 6.85 1.34 4.30 0.38
Uom mOsm/kg
Control 2492 314 2842 259 2538 106 {2219 22}b 2187 126
V,-ant 2013 506 1593 283 2332 423 2727 520 2702 685
CAP 2168 198 2411 216 2077 336 1841 330 2031 284
UNaT .uno1Imin
Control 0.30 0.07 0.35 0.07 {l.29 0.28}a {1.62 0.32}a {0.89 0.20}a
V,-ant 0.17 0.06 0.14 0.05 0.12 0.04c 0.12 003d 0.14 0.06c
CAP 0.20 0.05 0.25 0.09 1.52 1.09 1.16 0.62 0.46 0.15
UKV smol/min
Control 1.05 0.33 1.26 0.22 {3.17 0.24}a {2.95 0.40}" 1.87 0.26
V,-ant 0.27 0.06 0.36 0.07 0.53 0.08" 0.70 0.ll' 0.99 0.19
CAP 0.87 0.21 1.22 0.25 2.85 0.22 2.97 0.27 1.98 0.17
A
Urine flow rate (V), Urine osmolality (Usm), sodium excretion (UNaV) and potassium excretion (UKV) data are in "noHex control" receiving
AVP (control group N = 4), "noHex V,-ant" receiving AVP (V, group N = 4) and "noHex CAP" receiving AVP (CAP group N = 4). AVP was
infused in periods 2 and 3. All data are expressed as mean 5EM. The effects of administration of AVP on renal function was analyzed by ANOVA
with a repeated measures design, followed by the Tukey post hoc test applied within the control group (period 1 vs. each of 2, 3, 4,5;
a P < 0.05, { } "P < 0.01). Comparisons between groups were made with ANOVA using log transformed data, followed by the Bonferroni adjusted
1-test, C P < 0.05, d p < 0.01 compared with the corresponding values in the control group.
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Fig. 7. The mean (±sEM) values of MAP in OT 25 ng hr' kg-I
body WI infusion (—•, N = 6) and Ringers infusion (0—0, N = 5)
animals.
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Control AVP Sham AUN
Fig. 6A. Plasma concentration of OT in control (N = 9), OT 25
ng hr' kg_I infusion (N = 12), "vehicle sham" (N = 7) and
"vehicle A UN" (N = 12) groups. ** P < 0.01 from control or vehicle
sham groups based on unpaired 1-test applied between two groups.
Values are means SEM. B. The plasma concentration of AVP in
control (N = 4), AVP 25 ng hr' kg infusion (N = 2), "vehicle
sham" (N = 6)and "vehicle AUN" (N = 11) groups. Values are means
SEM.
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Accordingly, since the V1 antagonist d(CH2)5Tyr(Me)AVP
interacts with the OT-receptor, where CAP has lower affinity
for the V1- and V2-receptors of AVP [23, 24], it can be assumed
that a part of the V1-ant effects on sodium excretion can be an
effect of interference with the OT-receptor [25], though to a
lesser extent (Fig. 9).
On the other hand, although the V1 antagonist did not abolish
the postnephrectomy natriuresis, it diminished the renal elec-
trolyte and fluid excretion to a great extent, a fact that indicates
the tonic effects of vasculature V1-receptors on renal excretion.
Since d(CH2)5Tyr(Me)AVP is one of the most potent blockers
of V1-receptors and a weak OT-receptor antagonist in vivo [32],
we could not rule out the possibility that there was a mutually
complementry effect between vasopressin and oxytocin, as
there is evidence of a synergism of the natriuretic effects of OT
and AVP detected in neurohypophysectomized rats. Neurohy-
pophysectomy induces sodium retention. If administered in
small doses separately, neither OT nor AVP caused natriuresis,
but when given simultaneously, they greatly reversed the renal
sodium retention [10]. Also, there are some reports that OT is
more natriuretic when the rate of urine flow is relatively low, or
in other words when AVP is present [11], It may be that OT and
AVP are complementary to each other in the control of sodium
0.0
01 OT+V1 OT+CAP
Fig. 9. The change in UNa/ in "UT" (infused with UT only, N 6),
"OT V,-ant" (pre-infused with V,-ant, N = 5) and "UT CAP"
(pre-infused with CAP, N = 6)groups. Each bar represents the average
change 20 to 60 minutes after 25 ng' hr1 kg' body wt OT infusion.
** P < 0.01 from "OT" group based on unpaired I-test applied between
three groups for the average change 20 to 60 minutes after OT infusion.
excretion. If this is the case, then this mutual action would
make the renal regulating system more flexible for electrolyte
and water balance, and thereby more efficient.
As we did not measure the plasma AVP concentration
throughout the whole process, we cannot exclude a transient
rise in AVP concentration. For instance, in our vehicle AUN
group, most rats showed a transient rise of blood pressure after
AUN (Fig. 3). In dogs, this phenomenon has been claimed to be
an important trigger factor for postnephrectomy natriuresis
[18]. However, MAP tended to decrease rather then increase
during the maintenance period after AUN. That is, during the
time when the natriuresis was most pronounced blood pressure
was on its way down, eventually declining below the pre-AUN
level. Furthermore, CAP treated animals still responded to
AUN with the transient blood pressure increase (Fig. 3).
Nevertheless, these animals do not develop postnephrectomy
natriuresis as would be expected. Also in the other groups there
was no definite correlation between the transient rise of MAP
and subsequent natriuresis. Thus, it is not likely that the
systemic hemodynamic change is an important component of
the mechanism responsible for the postnephrectomy natriure-
sis. The important fact is that CAP treatment attenuated post-
nephrectomy natriuresis not by modifying such a MAP change;
there must be a nonhypertensive factor responsible for natri-
uresis seen after AUN. This finding is in agreement with the
results of our earlier intraventricular hyperosmotic stimulation
experiments which demonstrated the natriuretic effect of a
putative non-hypertensive hormone [16].
In the acute experiments, the maximal antidiuretic dose of
AVP had no effects on MAP or salt excretion. The natriuretic
effect of AVP was observed when the pressor action of the
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Fig. 8. The mean (±sEM) values of sodium excretion (UNQ'), potassium
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hormone was evident [15, 21]. In contrast, OT is a non-
hypertensive natriuretic hormone [12]. This makes OT more
likely a candidate for this putative non-hypertensive hormone.
For the first time evidence has been furnished that oxytocin
receptors play a major role in the acute readjustment of the
renal function in order to maintain sodium balance. Vasopressin
vascular V1-receptors seem to affect the magnitude of renal
water and electrolyte excretion and operate in synergism with
OT in regulating renal sodium excretion.
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